JACKSONVILLE, FL – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the closing of a private round of funding as well as an equity investment made by G. Pohl-Boskamp GmbH & Co. KG (Pohl-Boskamp), a fully-integrated German pharmaceutical company with a 175 year operating history.
Espero will use the proceeds to initiate commercialization activities as well as extend its business development efforts to license new products. “We have hit the ground running from day one,” said Quang Pham, founder, chairman & CEO. “Espero has successfully secured a global pharmaceutical partner, Pohl-Boskamp, as an investor and we look forward to our future collaborations.”
“This is our first investment in the U.S., driven in large part by our belief in the vision and ability of the Espero Team,” remarked Marianne Boskamp, CEO of Pohl-Boskamp. “We are excited about the opportunities available to us in the U.S. market and expect this to be the beginning of a very productive long-term relationship between our companies.”
Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories.
About G. Pohl-Boskamp GmbH & Co KG
Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for 175 years with commercialized products in more than 45 countries. Pohl-Boskamp focuses on collaborating closely with partners abroad and developing products that positively impact patient’s quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology. For more information, visit http://www.pohl-boskamp.com/en/.
For more information, contact:
MBS Value Partners, LLC